SPRC vs. CARM, GELS, LPCN, APRE, LPTX, MIRA, OKUR, COCP, NNVC, and GLYC
Should you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Carisma Therapeutics (CARM), Gelteq (GELS), Lipocine (LPCN), Aprea Therapeutics (APRE), Leap Therapeutics (LPTX), MIRA Pharmaceuticals (MIRA), OnKure Therapeutics (OKUR), Cocrystal Pharma (COCP), NanoViricides (NNVC), and GlycoMimetics (GLYC). These companies are all part of the "pharmaceutical products" industry.
SciSparc vs.
SciSparc (NASDAQ:SPRC) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
25.1% of SciSparc shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 1.5% of SciSparc shares are held by company insiders. Comparatively, 12.6% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
SciSparc has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500.
SciSparc has higher earnings, but lower revenue than Carisma Therapeutics.
Carisma Therapeutics received 15 more outperform votes than SciSparc when rated by MarketBeat users. Likewise, 77.27% of users gave Carisma Therapeutics an outperform vote while only 66.67% of users gave SciSparc an outperform vote.
Carisma Therapeutics has a consensus target price of $4.94, suggesting a potential upside of 966.95%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than SciSparc.
SciSparc has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -314.78%. SciSparc's return on equity of 0.00% beat Carisma Therapeutics' return on equity.
In the previous week, SciSparc had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 2 mentions for SciSparc and 1 mentions for Carisma Therapeutics. SciSparc's average media sentiment score of 1.08 beat Carisma Therapeutics' score of 0.00 indicating that SciSparc is being referred to more favorably in the media.
Summary
Carisma Therapeutics beats SciSparc on 10 of the 17 factors compared between the two stocks.
Get SciSparc News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SciSparc Competitors List
Related Companies and Tools
This page (NASDAQ:SPRC) was last updated on 2/22/2025 by MarketBeat.com Staff
